mTICI 2c (n=519) | mTICI 3 (n=1923) | OR (95% CI) | P value | |
Primary outcome | ||||
mRS 0–2 at 90 days, n (%) | 220/519 (42.4%) | 868/1923 (45.1%) | 1.118 (0.919 to 1.360) | 0.264 |
Secondary outcomes | ||||
mRS 0–2 at discharge, n (%) | 152/390 (39.0%) | 465/1115 (41.7%) | 1.120 (0.885 to 1.418) | 0.346 |
mRS 0–1 at 90 days, n (%) | 154/519 (29.7%) | 623/1923 (32.4%) | 1.136 (0.920 to 1.403) | 0.237 |
mRS 0–1 at discharge, n (%) | 112/390 (28.7%) | 328/1115 (29.4%) | 1.034 (0.802 to 1.334) | 0.794 |
Mortality at 90 days, n (%) | 100/519 (19.3%) | 331/1923 (17.2%) | 0.871 (0.680 to 1.117) | 0.276 |
Mortality at discharge, n (%) | 47/390 (12.1%) | 123/1115 (11.0%) | 0.905 (0.633 to 1.294) | 0.584 |
mRS at 90 days, median (IQR) | 3 (4) | 3 (3) | 0.860 (0.968 to 1.117) | 0.082 |
mRS at discharge, median (IQR) | 3 (4) | 3 (3) | 0.841 (0.687 to 1.029) | 0.093 |
NIHSS at discharge, median (IQR) | 8 (9) | 8 (10) | 0.348 (−0.747 to 1.442)* | 0.533 |
Any ICH, n (%) | 127/496 (25.6%) | 392/1704 (23.0%) | 0.868 (0.689 to 1.094) | 0.230 |
Symptomatic ICH, n (%) | 30/507 (5.9%) | 80/1737 (4.6%) | 0.768 (0.489 to 1.182) | 0.230 |
Procedure-related complications, n (%) | 19/327 (5.8%) | 61/1314 (4.6%) | 0.789 (0.465 to 1.341) | 0.381 |
*Beta value (95% CI) in linear regression.
mRS, modified Rankin Scale; ICH, intracerebral hemorrhage; NIHSS, National Institute of Health Stroke Scale; mTICI, modified Thrombolysis in Cerebral Ischemia.;